Abstract:Objective To investigate the effect of immunomodulator ribonucleic acid Ⅱ on anastrozole?related joint symptoms. Methods A total of 156 postmenopausal women patients with stage Ⅰ?Ⅲ breast cancer and anastrozole?related joint symp?toms were enrolled. These patients were divided into two groups:One group were treated by ribonucleic acid Ⅱ( 200 mg, intravenous infusion, 1 time a day) as the experimental group, the other was treated by saline as the control group. The degree of symptom change was evaluated by FACT?G and WOMAC. The levels of serum cytokines(IFN?γand IL?4), the bone gla protein(BGP), bone alkaline phosphatase(BALP) and I collagen carboxyl?terminal propeptide(CICP) of bone metabolism were detected by ELISA method. Results In comparison with the control group, ribonucleic acid Ⅱ significantly reduced the severity of musculoskeletal symptoms and pain, and also improved the quality of life( P<005) . In ribonucleic acid Ⅱ group, the blood level of IL?4 was increased, whereas IFN?γwas decreased( P<005) . as well as, the indexes of bone metabolism BALP and CICP were significantly lower than those in the control group( P<005) . Conclusion Ribonucleic acid Ⅱ could improve aromatase inhibitor related musculoskeletal symptoms by the role of immunity adjustment.

Effect of ribonucleic acid Ⅱ on anastrozole?related joint symptoms in postmenopausal breast cancer patients